Triton’s €2 Billion Sale of Specialty Pharma Firm Said to Stall

Triton’s plans to sell Pharmanovia are stalling over valuation, people familiar with knowledge of the matter said, in another sign that private equity firms are struggling to get deals over the line.

UK-based Triton has been running an auction process for the British specialty pharma business and seeking more than €2 billion ($2.2 billion) in a deal, according to the people.

Triton has been in discussions about selling Pharmanovia to private equity peer Permira, which already owns a European specialty pharma company called Neuraxpharm, but talks have faltered on price, they said.

Deliberations are ongoing and Triton continues ...